Idorsia 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
37 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ponvory (ponesimod) / Juvise Pharma, Vanda
DELIVER-MS, NCT03535298: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Active, not recruiting
4
800
Europe, US
Early Highly Effective Therapies Group, Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), Tysabri (natalizumab), Rituxan (rituximab), Kesimpta (ofatumumab), Briumvi (ublituximab), Escalation Therapies Group, Betaseron (beta interferon), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Extavia (beta interferon), Gilenya (fingolimod), Glatopa (glatiramer acetate), Plegridy (beta interferon), Rebif (beta interferon), Tecfidera (dimethyl fumarate), Avonex (beta interferon), Mavenclad (cladribine), Mayzent (siponimod), Vumerity (diroximel fumarate), Zeposia (ozanimod), Bafiertam (monomethyl fumarate), Ponvory (ponesimod)
The Cleveland Clinic, University of Nottingham
Multiple Sclerosis, Relapsing-Remitting
07/27
09/30
2020-004431-24: A Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ponesimod Versus Fingolimod During 108 Weeks of Treatment in Pediatric Participants, 10 to <18 Years Old, with Relapsing-remitting Multiple Sclerosis Estudio para evaluar la eficacia, seguridad, farmacocinética y farmacodinamia de ponesimod frente a fingolimod durante 108 semanas de tratamiento en pacientes pediátricos, de 10 a <18 años, con esclerosis múltiple remitente recurrente.

Ongoing
3
212
Europe, RoW
Ponesimod, Fingolimod, JNJ-67896153/ACT-128800, Film-coated tablet, Capsule, Gilenya hard capsules
Janssen-Cilag International NV, Janssen Research & Development, LLC
Relapsing-remitting Multiple Sclerosis Esclerosis múltiple remitente recurrente., Chronic inflammatory disease attacking the CNS Enfermedad inflamatoria crónica que ataca al SNC., Diseases [C] - Nervous System Diseases [C10]
 
 
OPTIMUM-LT, NCT03232073 / 2016-004719-10: Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis

Completed
3
877
Europe, Canada, US, RoW
Ponesimod
Actelion
Multiple Sclerosis
01/24
01/24
NCT01093326 / 2009-011470-15: Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis

Checkmark Current status of EXTENSION study in MS
Apr 2016 - Apr 2016: Current status of EXTENSION study in MS
Checkmark Extension study in MS
Apr 2015 - Apr 2015: Extension study in MS
Checkmark ECTRIMS 2013: Multiple sclerosis
More
Completed
2
353
Europe, Canada, US, RoW
Ponesimod 10 mg, Ponesimod 20 mg, Ponesimod 40 mg
Actelion
Multiple Sclerosis
09/23
09/23
NCT05552196: A Study of Ponesimod in Healthy Adult Participants

Completed
1
28
Europe
Ponesimod, JNJ-67896153, ACT-128800, Ponvory, Carbamazepine, Tegretol
Janssen Pharmaceutica N.V., Belgium
Healthy
03/23
03/23
CPE, NCT05762003: Czech Pharmaco-epidemiological Study on Disease Modifying Drugs

Completed
N/A
17478
RoW
interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab
IMPULS Endowment Fund
Multiple Sclerosis
12/21
12/21
TREAT-MS, NCT03500328: Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

Active, not recruiting
N/A
900
US
Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq, Tysabri, Lemtrada, Ocrevus, Rituxan/Riabni/Truxima/Ruxience, Mavenclad, Kesimpta, Briumvi, Ocrevus Zunovo, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod, Copaxone, Glatopa, Avonex, Betaseron, Extavia, Rebif, Plegridy, Aubagio, Tecfidera, Vumerity, Bafiertam, Gilenya, Mayzent, Zeposia, Ponvory, Tascenso
Johns Hopkins University, Patient-Centered Outcomes Research Institute, National Multiple Sclerosis Society
Multiple Sclerosis, Relapsing-Remitting
08/26
08/26
NCT05688436: A Study to Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate

Recruiting
N/A
1178
US
Diroximel Fumarate, VUMERITY, BIIB098, Alemtuzumab, Fingolimod, Glatiramer acetate, Interferon beta, Natalizumab, Tysabri, BG00002, Ocrelizumab, Ofatumumab, Ozanimod, Peginterferon beta-1a, Ponesimod, Siponimod
Biogen
Multiple Sclerosis
01/31
01/31
cenerimod (ACT-334441) / Viatris
2022-002814-17: A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

Not yet recruiting
3
420
Europe, RoW
Cenerimod, ACT-334441, Film-coated tablet
Idorsia Pharmaceuticals Ltd, Idorsia Pharmaceuticals Ltd
Moderate to severe systemic lupus erythematosus, Lupus, Diseases [C] - Immune System Diseases [C20]
 
 
2022-002815-47: A research study to evaluate the efficacy and safety of cenerimod in subjects suffering from Systemic Lupus Erythematosus

Not yet recruiting
3
420
Europe, RoW
Cenerimod, ACT-334441, Film-coated tablet
Idorsia Pharmaceuticals Ltd, Idorsia Pharmaceuticals Ltd
Moderate to severe systemic lupus erythematosus, Lupus, Diseases [C] - Immune System Diseases [C20]
 
 
OPUS OLE, NCT06475742: Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus

Enrolling by invitation
3
680
Europe, US, RoW
Cenerimod, ACT-334441
Idorsia Pharmaceuticals Ltd.
Lupus Erythematosus, Systemic
05/28
05/28
OPUS-2, NCT05672576 / 2022-002815-47: A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus

Recruiting
3
420
Europe, Japan, US, RoW
Cenerimod, ACT-334441, Placebo
Idorsia Pharmaceuticals Ltd., Idorsia Pharmaceuticals Ltd
Lupus Erythematosus, Systemic
10/26
05/27
OPUS-1, NCT05648500 / 2022-002814-17: A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

Recruiting
3
420
Europe, US, RoW
Cenerimod, ACT-334441, Placebo
Idorsia Pharmaceuticals Ltd., Idorsia Pharmaceuticals Ltd
Lupus Erythematosus, Systemic
10/26
05/27
NCT05004311: The Effect of Severe Kidney Impairment on Cenerimod Pharmacokinetics

Completed
1
16
Europe
Cenerimod, ACT-334441
Idorsia Pharmaceuticals Ltd.
Healthy, Renal Impairment
07/23
08/23
NCT04819464: A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of Cenerimod

Completed
1
24
Europe
Cenerimod, ACT-334441
Idorsia Pharmaceuticals Ltd.
Healthy, Hepatic Impairment
08/24
08/24
Tryvio (aprocitentan) / J&J
NCT06799884: A Drug-drug Interaction Trial in Healthy Female Participants to Investigate the Effect of Aprocitentan on Combined Hormonal Contraceptives

Completed
1
19
RoW
Ethinyl Estradiol / Levonorgestrel Oral Tablet, LOETTE, Aprocitentan
Idorsia Pharmaceuticals Ltd.
Drug Drug Interaction
02/25
02/25
Quviviq (daridorexant) / Idorsia, Syneos Health, Nxera Pharma
NCT05597020: A Study to Find Out if Daridorexant is Safe and Efficacious in Patients With Insomnia and Comorbid Nocturia

Completed
4
60
Europe, US
Daridorexant, Placebo
Idorsia Pharmaceuticals Ltd.
Insomnia Disorder, Nocturia
04/24
04/24
DARIDOR-ALZ, NCT05924425: Daridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to Moderate Alzheimer Disease

Recruiting
4
62
Europe
Daridorexant 50 mg, Placebo, Polysomnography, Neuropsychological assessment, Questionnaires on sleep and behavioural problems, Actimetrics, 24-hour Ambulatory Blood Pressure Monitoring (ABPM, Biomarker assay
University Hospital, Montpellier, Idorsia Pharmaceuticals Ltd.
Alzheimer Disease, Insomnia Disorder, Sleep
05/26
03/27
NCT07028697: A Study to Evaluate the Efficacy and Safety of Daridorexant in Participants With Insomnia Disorder

Recruiting
3
160
RoW
Daridorexant, Placebo
Nxera Pharma Korea Co., Ltd.
Insomnia Disorder
10/25
10/25
NCT06010693: A Study of Daridorexant in Chinese Patients With Insomnia Disorder

Completed
3
206
RoW
Daridorexant, Placebo
Jiangsu Simcere Pharmaceutical Co., Ltd.
Insomnia Disorder
04/24
05/24
NCT06630390: Daridorexant to Prevent Delirium After Heart Surgery

Completed
2
11
US
Daridorexant 50 mg, Placebo
University of Rochester
POSTOPERATIVE DELIRIUM, POSTOPERATIVE COGNITIVE DECLINE
02/25
02/25
NCT05423717 / 2021-003867-87: Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to < 18 Years With Insomnia Disorder

Recruiting
2
150
Europe, US
Daridorexant 10 mg, Daridorexant 25 mg, Daridorexant 50 mg, Placebo
Idorsia Pharmaceuticals Ltd., Idorsia Pharmaceuticals Ltd
Insomnia
03/26
04/26
NCT05948540: Department of Defense PTSD Adaptive Platform Trial - Intervention C - Daridorexant

Recruiting
2
200
US
Intervention C Daridorexant, Intervention C Placebo
Global Coalition for Adaptive Research, U.S. Army Medical Research and Development Command, PPD Development, LP, Berry Consultants, Idorsia Pharmaceuticals Ltd., Cambridge Cognition Ltd, Citeline
Post Traumatic Stress Disorder
03/26
09/26
NCT05422612: Department of Defense PTSD Adaptive Platform Trial - Master Protocol

Recruiting
2
800
US
Intervention A Fluoxetine Hydrochloride (HCl), Intervention A Placebo, Intervention B Vilazodone Hydrochloride (HCl), Intervention B Placebo, Intervention C Daridorexant, Intervention C Placebo, Intervention D SLS-002, Intervention D Placebo
Global Coalition for Adaptive Research, U.S. Army Medical Research and Development Command, PPD Development, LP, Berry Consultants, Idorsia Pharmaceuticals Ltd., Cambridge Cognition Ltd, Citeline
Post Traumatic Stress Disorder
03/26
09/26
NCT03686995: Study to Evaluate the PK of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Impairment

Not yet recruiting
1
32
Europe
ACT-541468
University Hospital, Basel, Switzerland, Idorsia Pharmaceuticals Ltd.
Hepatic Impairment
06/19
06/19
NCT05458193: A Study to Investigate the Effects of Daridorexant on Nighttime Breathing in Patients With Shallow or Paused Breath During Sleep

Completed
1
20
Europe
Daridorexant, ACT-541468, Placebo
Idorsia Pharmaceuticals Ltd.
Obstructive Sleep Apnea of Adult
02/23
02/23
NCT05702177: A Study of the Effect of Daridorexant on Nighttime Body Posture, the Noise Level Required to Wake up, and the Ability to Remember Words Previously Presented

Completed
1
36
Europe
Daridorexant 25 mg, Quviviq, Daridorexant 50 mg, Placebo
Idorsia Pharmaceuticals Ltd.
Healthy
04/23
04/23
NCT05632393: A Study to Measure Daridorexant in Breast Milk of Healthy Lactating Women

Completed
1
10
US
Daridorexant
Idorsia Pharmaceuticals Ltd.
Healthy
04/23
04/23
NCT05877222: A Phase 1 Trial to Investigate the Biological Equivalence of 5 × 10 mg Tablets and 2 × 25 mg Tablets of Daridorexant in Healthy Male and Female Japanese Participants

Completed
1
38
US
Daridorexant 10 mg, Daridorexant 25 mg
Idorsia Pharmaceuticals Ltd.
Healthy
08/23
08/23
NCT06326723: Investigate the PK, Safety, and Tolerability After Single and Multiple Dose Daridorexant in Chinese Healthy Subjects

Completed
1
32
RoW
Daridorexant
Jiangsu Simcere Pharmaceutical Co., Ltd.
Healthy Volunteer
12/23
02/24
NCT06393504: Database Study to Provide Information on Pregnancy and Infant Outcomes Among Women Exposed to QUVIVIQ (Daridorexant)

Active, not recruiting
N/A
2095
US
Daridorexant, QUVIVIQ, Non-orexin receptor antagonist insomnia medication, No insomnia medication
Idorsia Pharmaceuticals Ltd., Carelon Research
Insomnia Disorder
04/28
04/28
NCT06311864: Real-World Observational Study on Patient-Reported Outcomes in the Treatment of Insomnia with Daridorexant in Canada

Enrolling by invitation
N/A
100
Canada
Daridorexant 50 mg, QUVIVIQ
PeriPharm, Idorsia Pharmaceuticals Ltd.
Insomnia
10/25
10/25
NCT06498128: Registry to Collect Information on Pregnancy, Neonatal, and Infant Outcomes in Pregnant Women Exposed to QUVIVIQ®

Recruiting
N/A
785
Europe, Canada, US
Daridorexant, QUVIVIQ, Non-orexin receptor antagonist medications for insomnia, No insomnia medication
Idorsia Pharmaceuticals Ltd., Iqvia Pty Ltd
Insomnia
03/33
03/33
NBI-827104 / Neurocrine
Steamboat 2, NCT05301894 / 2021-006788-11: Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep

Terminated
2
19
Europe, US
NBI-827104
Neurocrine Biosciences
Epileptic Encephalopathy, Continuous Spike and Wave During Sleep
01/25
01/25
lucerastat (ACT-434964) / Idorsia
NCT03737214 / 2018-002210-12: A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease

Active, not recruiting
3
107
Europe, Canada, US, RoW
Lucerastat
Idorsia Pharmaceuticals Ltd.
Fabry Disease
08/29
11/29
selatogrel (ACT-246475) / Viatris
SOS-AMI, NCT04957719 / 2020-000983-41: Selatogrel Outcome Study in Suspected Acute Myocardial Infarction

Enrolling by invitation
3
14000
Europe, Canada, US, RoW
Selatogrel, ACT-246475, Placebo
Viatris Innovation GmbH, Idorsia, Idorsia Pharmaceuticals Ltd
Acute Myocardial Infarction
08/25
08/25
2018-000765-36: A medical research study to evaluate the effects of ACT-245475 in adults with heart attack

Not yet recruiting
2
42
Europe
ACT-246475, ACT-246475, Lyophilisate for solution for injection
Idorsia Pharmaceuticals Ltd, Idorsia Pharmaceuticals Ltd
Acute myocardial infarction, Myocardial infarction, also known as heart attack is when a clot is blocking the blood flow through the vessels that carry the blood to the heart muscle (the coronary arteries), Diseases [C] - Cardiovascular Diseases [C14]
 
 
Pivlaz (clazosentan) / Idorsia, Nxera Pharma
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ponvory (ponesimod) / Juvise Pharma, Vanda
DELIVER-MS, NCT03535298: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Active, not recruiting
4
800
Europe, US
Early Highly Effective Therapies Group, Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), Tysabri (natalizumab), Rituxan (rituximab), Kesimpta (ofatumumab), Briumvi (ublituximab), Escalation Therapies Group, Betaseron (beta interferon), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Extavia (beta interferon), Gilenya (fingolimod), Glatopa (glatiramer acetate), Plegridy (beta interferon), Rebif (beta interferon), Tecfidera (dimethyl fumarate), Avonex (beta interferon), Mavenclad (cladribine), Mayzent (siponimod), Vumerity (diroximel fumarate), Zeposia (ozanimod), Bafiertam (monomethyl fumarate), Ponvory (ponesimod)
The Cleveland Clinic, University of Nottingham
Multiple Sclerosis, Relapsing-Remitting
07/27
09/30
2020-004431-24: A Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ponesimod Versus Fingolimod During 108 Weeks of Treatment in Pediatric Participants, 10 to <18 Years Old, with Relapsing-remitting Multiple Sclerosis Estudio para evaluar la eficacia, seguridad, farmacocinética y farmacodinamia de ponesimod frente a fingolimod durante 108 semanas de tratamiento en pacientes pediátricos, de 10 a <18 años, con esclerosis múltiple remitente recurrente.

Ongoing
3
212
Europe, RoW
Ponesimod, Fingolimod, JNJ-67896153/ACT-128800, Film-coated tablet, Capsule, Gilenya hard capsules
Janssen-Cilag International NV, Janssen Research & Development, LLC
Relapsing-remitting Multiple Sclerosis Esclerosis múltiple remitente recurrente., Chronic inflammatory disease attacking the CNS Enfermedad inflamatoria crónica que ataca al SNC., Diseases [C] - Nervous System Diseases [C10]
 
 
OPTIMUM-LT, NCT03232073 / 2016-004719-10: Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis

Completed
3
877
Europe, Canada, US, RoW
Ponesimod
Actelion
Multiple Sclerosis
01/24
01/24
NCT01093326 / 2009-011470-15: Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis

Checkmark Current status of EXTENSION study in MS
Apr 2016 - Apr 2016: Current status of EXTENSION study in MS
Checkmark Extension study in MS
Apr 2015 - Apr 2015: Extension study in MS
Checkmark ECTRIMS 2013: Multiple sclerosis
More
Completed
2
353
Europe, Canada, US, RoW
Ponesimod 10 mg, Ponesimod 20 mg, Ponesimod 40 mg
Actelion
Multiple Sclerosis
09/23
09/23
NCT05552196: A Study of Ponesimod in Healthy Adult Participants

Completed
1
28
Europe
Ponesimod, JNJ-67896153, ACT-128800, Ponvory, Carbamazepine, Tegretol
Janssen Pharmaceutica N.V., Belgium
Healthy
03/23
03/23
CPE, NCT05762003: Czech Pharmaco-epidemiological Study on Disease Modifying Drugs

Completed
N/A
17478
RoW
interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab
IMPULS Endowment Fund
Multiple Sclerosis
12/21
12/21
TREAT-MS, NCT03500328: Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

Active, not recruiting
N/A
900
US
Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq, Tysabri, Lemtrada, Ocrevus, Rituxan/Riabni/Truxima/Ruxience, Mavenclad, Kesimpta, Briumvi, Ocrevus Zunovo, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod, Copaxone, Glatopa, Avonex, Betaseron, Extavia, Rebif, Plegridy, Aubagio, Tecfidera, Vumerity, Bafiertam, Gilenya, Mayzent, Zeposia, Ponvory, Tascenso
Johns Hopkins University, Patient-Centered Outcomes Research Institute, National Multiple Sclerosis Society
Multiple Sclerosis, Relapsing-Remitting
08/26
08/26
NCT05688436: A Study to Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate

Recruiting
N/A
1178
US
Diroximel Fumarate, VUMERITY, BIIB098, Alemtuzumab, Fingolimod, Glatiramer acetate, Interferon beta, Natalizumab, Tysabri, BG00002, Ocrelizumab, Ofatumumab, Ozanimod, Peginterferon beta-1a, Ponesimod, Siponimod
Biogen
Multiple Sclerosis
01/31
01/31
cenerimod (ACT-334441) / Viatris
2022-002814-17: A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

Not yet recruiting
3
420
Europe, RoW
Cenerimod, ACT-334441, Film-coated tablet
Idorsia Pharmaceuticals Ltd, Idorsia Pharmaceuticals Ltd
Moderate to severe systemic lupus erythematosus, Lupus, Diseases [C] - Immune System Diseases [C20]
 
 
2022-002815-47: A research study to evaluate the efficacy and safety of cenerimod in subjects suffering from Systemic Lupus Erythematosus

Not yet recruiting
3
420
Europe, RoW
Cenerimod, ACT-334441, Film-coated tablet
Idorsia Pharmaceuticals Ltd, Idorsia Pharmaceuticals Ltd
Moderate to severe systemic lupus erythematosus, Lupus, Diseases [C] - Immune System Diseases [C20]
 
 
OPUS OLE, NCT06475742: Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus

Enrolling by invitation
3
680
Europe, US, RoW
Cenerimod, ACT-334441
Idorsia Pharmaceuticals Ltd.
Lupus Erythematosus, Systemic
05/28
05/28
OPUS-2, NCT05672576 / 2022-002815-47: A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus

Recruiting
3
420
Europe, Japan, US, RoW
Cenerimod, ACT-334441, Placebo
Idorsia Pharmaceuticals Ltd., Idorsia Pharmaceuticals Ltd
Lupus Erythematosus, Systemic
10/26
05/27
OPUS-1, NCT05648500 / 2022-002814-17: A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

Recruiting
3
420
Europe, US, RoW
Cenerimod, ACT-334441, Placebo
Idorsia Pharmaceuticals Ltd., Idorsia Pharmaceuticals Ltd
Lupus Erythematosus, Systemic
10/26
05/27
NCT05004311: The Effect of Severe Kidney Impairment on Cenerimod Pharmacokinetics

Completed
1
16
Europe
Cenerimod, ACT-334441
Idorsia Pharmaceuticals Ltd.
Healthy, Renal Impairment
07/23
08/23
NCT04819464: A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of Cenerimod

Completed
1
24
Europe
Cenerimod, ACT-334441
Idorsia Pharmaceuticals Ltd.
Healthy, Hepatic Impairment
08/24
08/24
Tryvio (aprocitentan) / J&J
NCT06799884: A Drug-drug Interaction Trial in Healthy Female Participants to Investigate the Effect of Aprocitentan on Combined Hormonal Contraceptives

Completed
1
19
RoW
Ethinyl Estradiol / Levonorgestrel Oral Tablet, LOETTE, Aprocitentan
Idorsia Pharmaceuticals Ltd.
Drug Drug Interaction
02/25
02/25
Quviviq (daridorexant) / Idorsia, Syneos Health, Nxera Pharma
NCT05597020: A Study to Find Out if Daridorexant is Safe and Efficacious in Patients With Insomnia and Comorbid Nocturia

Completed
4
60
Europe, US
Daridorexant, Placebo
Idorsia Pharmaceuticals Ltd.
Insomnia Disorder, Nocturia
04/24
04/24
DARIDOR-ALZ, NCT05924425: Daridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to Moderate Alzheimer Disease

Recruiting
4
62
Europe
Daridorexant 50 mg, Placebo, Polysomnography, Neuropsychological assessment, Questionnaires on sleep and behavioural problems, Actimetrics, 24-hour Ambulatory Blood Pressure Monitoring (ABPM, Biomarker assay
University Hospital, Montpellier, Idorsia Pharmaceuticals Ltd.
Alzheimer Disease, Insomnia Disorder, Sleep
05/26
03/27
NCT07028697: A Study to Evaluate the Efficacy and Safety of Daridorexant in Participants With Insomnia Disorder

Recruiting
3
160
RoW
Daridorexant, Placebo
Nxera Pharma Korea Co., Ltd.
Insomnia Disorder
10/25
10/25
NCT06010693: A Study of Daridorexant in Chinese Patients With Insomnia Disorder

Completed
3
206
RoW
Daridorexant, Placebo
Jiangsu Simcere Pharmaceutical Co., Ltd.
Insomnia Disorder
04/24
05/24
NCT06630390: Daridorexant to Prevent Delirium After Heart Surgery

Completed
2
11
US
Daridorexant 50 mg, Placebo
University of Rochester
POSTOPERATIVE DELIRIUM, POSTOPERATIVE COGNITIVE DECLINE
02/25
02/25
NCT05423717 / 2021-003867-87: Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to < 18 Years With Insomnia Disorder

Recruiting
2
150
Europe, US
Daridorexant 10 mg, Daridorexant 25 mg, Daridorexant 50 mg, Placebo
Idorsia Pharmaceuticals Ltd., Idorsia Pharmaceuticals Ltd
Insomnia
03/26
04/26
NCT05948540: Department of Defense PTSD Adaptive Platform Trial - Intervention C - Daridorexant

Recruiting
2
200
US
Intervention C Daridorexant, Intervention C Placebo
Global Coalition for Adaptive Research, U.S. Army Medical Research and Development Command, PPD Development, LP, Berry Consultants, Idorsia Pharmaceuticals Ltd., Cambridge Cognition Ltd, Citeline
Post Traumatic Stress Disorder
03/26
09/26
NCT05422612: Department of Defense PTSD Adaptive Platform Trial - Master Protocol

Recruiting
2
800
US
Intervention A Fluoxetine Hydrochloride (HCl), Intervention A Placebo, Intervention B Vilazodone Hydrochloride (HCl), Intervention B Placebo, Intervention C Daridorexant, Intervention C Placebo, Intervention D SLS-002, Intervention D Placebo
Global Coalition for Adaptive Research, U.S. Army Medical Research and Development Command, PPD Development, LP, Berry Consultants, Idorsia Pharmaceuticals Ltd., Cambridge Cognition Ltd, Citeline
Post Traumatic Stress Disorder
03/26
09/26
NCT03686995: Study to Evaluate the PK of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Impairment

Not yet recruiting
1
32
Europe
ACT-541468
University Hospital, Basel, Switzerland, Idorsia Pharmaceuticals Ltd.
Hepatic Impairment
06/19
06/19
NCT05458193: A Study to Investigate the Effects of Daridorexant on Nighttime Breathing in Patients With Shallow or Paused Breath During Sleep

Completed
1
20
Europe
Daridorexant, ACT-541468, Placebo
Idorsia Pharmaceuticals Ltd.
Obstructive Sleep Apnea of Adult
02/23
02/23
NCT05702177: A Study of the Effect of Daridorexant on Nighttime Body Posture, the Noise Level Required to Wake up, and the Ability to Remember Words Previously Presented

Completed
1
36
Europe
Daridorexant 25 mg, Quviviq, Daridorexant 50 mg, Placebo
Idorsia Pharmaceuticals Ltd.
Healthy
04/23
04/23
NCT05632393: A Study to Measure Daridorexant in Breast Milk of Healthy Lactating Women

Completed
1
10
US
Daridorexant
Idorsia Pharmaceuticals Ltd.
Healthy
04/23
04/23
NCT05877222: A Phase 1 Trial to Investigate the Biological Equivalence of 5 × 10 mg Tablets and 2 × 25 mg Tablets of Daridorexant in Healthy Male and Female Japanese Participants

Completed
1
38
US
Daridorexant 10 mg, Daridorexant 25 mg
Idorsia Pharmaceuticals Ltd.
Healthy
08/23
08/23
NCT06326723: Investigate the PK, Safety, and Tolerability After Single and Multiple Dose Daridorexant in Chinese Healthy Subjects

Completed
1
32
RoW
Daridorexant
Jiangsu Simcere Pharmaceutical Co., Ltd.
Healthy Volunteer
12/23
02/24
NCT06393504: Database Study to Provide Information on Pregnancy and Infant Outcomes Among Women Exposed to QUVIVIQ (Daridorexant)

Active, not recruiting
N/A
2095
US
Daridorexant, QUVIVIQ, Non-orexin receptor antagonist insomnia medication, No insomnia medication
Idorsia Pharmaceuticals Ltd., Carelon Research
Insomnia Disorder
04/28
04/28
NCT06311864: Real-World Observational Study on Patient-Reported Outcomes in the Treatment of Insomnia with Daridorexant in Canada

Enrolling by invitation
N/A
100
Canada
Daridorexant 50 mg, QUVIVIQ
PeriPharm, Idorsia Pharmaceuticals Ltd.
Insomnia
10/25
10/25
NCT06498128: Registry to Collect Information on Pregnancy, Neonatal, and Infant Outcomes in Pregnant Women Exposed to QUVIVIQ®

Recruiting
N/A
785
Europe, Canada, US
Daridorexant, QUVIVIQ, Non-orexin receptor antagonist medications for insomnia, No insomnia medication
Idorsia Pharmaceuticals Ltd., Iqvia Pty Ltd
Insomnia
03/33
03/33
NBI-827104 / Neurocrine
Steamboat 2, NCT05301894 / 2021-006788-11: Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep

Terminated
2
19
Europe, US
NBI-827104
Neurocrine Biosciences
Epileptic Encephalopathy, Continuous Spike and Wave During Sleep
01/25
01/25
lucerastat (ACT-434964) / Idorsia
NCT03737214 / 2018-002210-12: A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease

Active, not recruiting
3
107
Europe, Canada, US, RoW
Lucerastat
Idorsia Pharmaceuticals Ltd.
Fabry Disease
08/29
11/29
selatogrel (ACT-246475) / Viatris
SOS-AMI, NCT04957719 / 2020-000983-41: Selatogrel Outcome Study in Suspected Acute Myocardial Infarction

Enrolling by invitation
3
14000
Europe, Canada, US, RoW
Selatogrel, ACT-246475, Placebo
Viatris Innovation GmbH, Idorsia, Idorsia Pharmaceuticals Ltd
Acute Myocardial Infarction
08/25
08/25
2018-000765-36: A medical research study to evaluate the effects of ACT-245475 in adults with heart attack

Not yet recruiting
2
42
Europe
ACT-246475, ACT-246475, Lyophilisate for solution for injection
Idorsia Pharmaceuticals Ltd, Idorsia Pharmaceuticals Ltd
Acute myocardial infarction, Myocardial infarction, also known as heart attack is when a clot is blocking the blood flow through the vessels that carry the blood to the heart muscle (the coronary arteries), Diseases [C] - Cardiovascular Diseases [C14]
 
 
Pivlaz (clazosentan) / Idorsia, Nxera Pharma
No trials found

Download Options